Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 1
1996 2
1997 3
1998 7
1999 7
2000 2
2001 6
2002 4
2003 7
2004 6
2005 14
2006 13
2007 4
2008 2
2009 2
2010 1
2012 1
2014 2
2015 1
2017 2
2021 3
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Hemoglobin allostery and pharmacology.
Bellelli A, Tame JRH. Bellelli A, et al. Mol Aspects Med. 2022 Apr;84:101037. doi: 10.1016/j.mam.2021.101037. Epub 2021 Sep 30. Mol Aspects Med. 2022. PMID: 34600771 Review.
Effective and safe drugs such as voxelotor, bezafibrate and efaproxiral are available that significantly increase or decrease Hb oxygen affinity. ...
Effective and safe drugs such as voxelotor, bezafibrate and efaproxiral are available that significantly increase or decrease Hb oxyg …
Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
Stea B, Shaw E, Pintér T, Hackman J, Craig M, May J, Steffen RP, Suh JH. Stea B, et al. Br J Cancer. 2006 Jun 19;94(12):1777-84. doi: 10.1038/sj.bjc.6603169. Br J Cancer. 2006. PMID: 16773073 Free PMC article. Clinical Trial.
Patients with breast cancer primary tumours generally achieved the target efaproxiral exposure and therefore gained greater benefit from efaproxiral treatment than NSCLC patients. This analysis defined the efaproxiral concentration-dependence in survival and …
Patients with breast cancer primary tumours generally achieved the target efaproxiral exposure and therefore gained greater benefit f …
Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
Charpentier MM. Charpentier MM. Ann Pharmacother. 2005 Dec;39(12):2038-45. doi: 10.1345/aph.1G077. Epub 2005 Oct 25. Ann Pharmacother. 2005. PMID: 16249270 Review.
OBJECTIVE: To review the mechanism of action and clinical data of efaproxiral use in brain metastases of breast cancer. DATA SOURCES: Articles were identified through MEDLINE (1966-June 2005) and EMBASE (1980-May 2005) searches using the key words efaproxiral and RS …
OBJECTIVE: To review the mechanism of action and clinical data of efaproxiral use in brain metastases of breast cancer. DATA SOURCES: …
Role of efaproxiral in metastatic brain tumors.
Engel RH, Kaklamani VG. Engel RH, et al. Expert Rev Anticancer Ther. 2006 Apr;6(4):477-85. doi: 10.1586/14737140.6.4.477. Expert Rev Anticancer Ther. 2006. PMID: 16613536 Review.
After modifications to enhance absorption into the red blood cell, RSR13 (efaproxiral) was developed. Efaproxiral was found to be safe and improved tumor oxygenation in preclinical studies. ...Furthermore, the combination of efaproxiral with radiotherapy is b …
After modifications to enhance absorption into the red blood cell, RSR13 (efaproxiral) was developed. Efaproxiral was found to …
Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
Suh JH, Stea B, Nabid A, Kresl JJ, Fortin A, Mercier JP, Senzer N, Chang EL, Boyd AP, Cagnoni PJ, Shaw E. Suh JH, et al. J Clin Oncol. 2006 Jan 1;24(1):106-14. doi: 10.1200/JCO.2004.00.1768. Epub 2005 Nov 28. J Clin Oncol. 2006. PMID: 16314619 Clinical Trial.
PATIENTS AND METHODS: Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either efaproxiral at 75 or 100 mg/kg (efaproxiral arm) or no efaproxiral …
PATIENTS AND METHODS: Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assig …
Current therapeutic approaches in patients with brain metastases.
Peacock KH, Lesser GJ. Peacock KH, et al. Curr Treat Options Oncol. 2006 Nov;7(6):479-89. doi: 10.1007/s11864-006-0023-8. Curr Treat Options Oncol. 2006. PMID: 17032560 Review.
Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexafin in patients with metastatic lung cancer and efaproxiral in patients with metastatic breast cancer are ongoing. ...
Noncytotoxic radiosensitizing agents such as motexafin and efaproxiral show promise. Phase III trials to assess the benefit of motexa …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Methods Find Exp Clin Pharmacol. 2004. PMID: 14988742 Review.
This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaforsen sodium, almotriptan, alpharadin, anakinra, anatumomab mafenatox, ANG-453, anti-CTLA-4 Mab, AP-12009, aprepitant, aripiprazole, arsenic …
This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaf …
Efaproxiral: a novel radiation sensitiser.
Suh JH. Suh JH. Expert Opin Investig Drugs. 2004 May;13(5):543-50. doi: 10.1517/13543784.13.5.543. Expert Opin Investig Drugs. 2004. PMID: 15155129 Clinical Trial.
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. ...Since hypoxia is known to decrease the effectiveness of radiation therapy, the use of efaproxiral as a radiation sensitiser may be advantageous. Unlike …
Efaproxiral (RSR13) is a synthetic allosteric modifier of haemoglobin that reduces its oxygen binding affinity. ...Since hypoxia is k …
Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E; REACH Study Group. Stea B, et al. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1023-30. doi: 10.1016/j.ijrobp.2005.10.004. Epub 2006 Jan 30. Int J Radiat Oncol Biol Phys. 2006. PMID: 16446056 Clinical Trial.
RESULTS: Treatment arm, Karnofsky Performance Status, presence or absence of liver metastases, and primary site were all determinants of response at the 3-month follow-up visit, with patients in the efaproxiral arm experiencing a 67% greater odds of response at this visit …
RESULTS: Treatment arm, Karnofsky Performance Status, presence or absence of liver metastases, and primary site were all determinants of res …
Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
[No authors listed] [No authors listed] Drugs R D. 2005;6(3):178-85. doi: 10.2165/00126839-200506030-00007. Drugs R D. 2005. PMID: 15869322 Review.
Efaproxiral also received fast-track status in November 2000 for the same indication in the US. ...These patents cover methods of allosterically modifying haemoglobin with efaproxiral and other compounds, the binding site of efaproxiral and therapy in certain …
Efaproxiral also received fast-track status in November 2000 for the same indication in the US. ...These patents cover methods of all …
93 results